Stoke Therapeutics, Inc.
STOK
$31.38
-$1.11-3.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -83.20% | 404.50% | 1,128.17% | 1,218.82% | 2,333.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -83.20% | 404.50% | 1,128.17% | 1,218.82% | 2,333.50% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -83.20% | 404.50% | 1,128.17% | 1,218.82% | 2,333.50% |
| SG&A Expenses | 36.04% | 37.50% | 26.26% | 25.63% | 28.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.36% | 48.64% | 33.12% | 23.07% | 20.88% |
| Operating Income | -584.41% | 79.69% | 123.18% | 135.17% | 132.28% |
| Income Before Tax | -431.80% | 92.26% | 138.47% | 151.91% | 147.50% |
| Income Tax Expenses | -200.00% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -437.70% | 92.26% | 138.47% | 150.68% | 146.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -437.70% | 92.26% | 138.47% | 150.68% | 146.32% |
| EBIT | -584.41% | 79.69% | 123.18% | 135.17% | 132.28% |
| EBITDA | -555.00% | 81.03% | 125.29% | 137.69% | 134.76% |
| EPS Basic | -432.51% | 97.64% | 133.83% | 140.98% | 134.62% |
| Normalized Basic EPS | -426.48% | 97.67% | 133.85% | 141.99% | 135.53% |
| EPS Diluted | -455.58% | 94.35% | 131.33% | 138.56% | 132.43% |
| Normalized Diluted EPS | -447.10% | 94.64% | 131.42% | 139.66% | 133.42% |
| Average Basic Shares Outstanding | 6.64% | 9.98% | 14.04% | 20.05% | 26.35% |
| Average Diluted Shares Outstanding | 5.92% | 10.69% | 14.80% | 20.86% | 27.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |